^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MBRC-101
i
Other names: MBRC-101
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
MBrace Therap
Drug class:
Microtubule inhibitor, EPHA5-targeted antibody-drug conjugate
Related drugs:
11ms
Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors (clinicaltrials.gov)
P1, N=90, Recruiting, MBrace Therapeutics
Trial completion date • Trial initiation date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • EPHA5 (EPH Receptor A5)
|
HR positive • HER-2 negative • PTEN mutation + HR positive
|
MBRC-101
1year
Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors (clinicaltrials.gov)
P1, N=90, Recruiting, MBrace Therapeutics | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • EPHA5 (EPH Receptor A5)
|
HR positive • HER-2 negative
|
MBRC-101
1year
Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors (clinicaltrials.gov)
P1, N=90, Not yet recruiting, MBrace Therapeutics
New P1 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • EPHA5 (EPH Receptor A5)
|
HR positive • HER-2 negative
|
MBRC-101
Share via
